Faiz Qamar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Faiz Qamar has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Manju Sharma
Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India
4 shared publications - Divya Vohora
Department of Pharmacology, School of Pharmaceutical Education and Research (SPER), Jamia Hamdard, New Delhi, India
3 shared publications - Tufail Ahmad
Department of Pharmacology, School of Pharmaceutical Education and Research (SPER), Jamia Hamdard, New Delhi, India
2 shared publications - Mohd Vaseem
Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India
1 shared publication - Ramsha Parveen
Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research (SPER), Jamia Hamdard, New Delhi, India
1 shared publication Shradha Shaili
1 shared publication
Latest Publications
- 10 August 2026
- Published by Springer Nature in Inflammopharmacology
- Vol. 34 (9) , 5901-5917
From xanthine oxidase inhibition to inflammasome regulation: exploring the potential role of allopurinol in TXNIP–NLRP3 signaling and pyroptosis in diabetes
- 10 August 2026
- Published by Springer Nature in Inflammopharmacology
- Vol. 34 (9) , 5901-5917
From xanthine oxidase inhibition to inflammasome regulation: exploring the potential role of allopurinol in TXNIP–NLRP3 signaling and pyroptosis in diabetes
- 14 July 2026
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 127 (9) , 3983-3994
Pharmacological Evaluation of Bexagliflozin Monotherapy and Combination Therapy with Rutin in Streptozotocin-Induced Diabetes-Associated Cardiac Injury in Rats
- 14 July 2026
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 127 (9) , 3983-3994
Pharmacological Evaluation of Bexagliflozin Monotherapy and Combination Therapy with Rutin in Streptozotocin-Induced Diabetes-Associated Cardiac Injury in Rats
- 14 July 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (7) , e70780
Allopurinol Beyond Gout: Targeting Oxidative Stress and Metabolic Inflammation in Diabetes and Its Complications
- 14 July 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (7) , e70780
Allopurinol Beyond Gout: Targeting Oxidative Stress and Metabolic Inflammation in Diabetes and Its Complications
- 23 June 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 986
From sugar to flames: the detrimental role of pyroptosis in diabetes-associated bone loss
Diabetes mellitus (DM) is increasingly recognized as a major risk factor for skeletal fragility, characterized by impaired bone quality and increased fracture susceptibility. Chronic hyperglycemia induces metabolic stress, oxidative injury, and low-grade inflammation, all of which disrupt normal bone remodeling. Accumulating evidence indicates that pyroptosis, a highly inflammatory form of programmed cell death, has emerged as a critical mechanistic link between diabetes and bone loss. Pyroptosis is driven by inflammasome activation, particularly the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, leading to caspase-1 activation, gasdermin-mediated membrane pore formation, and the release of pro-inflammatory cytokines such as interleukin-1β (IL-1β) and interleukin-18 (IL-18). In the diabetic bone microenvironment, pyroptosis affects all major bone cell types. Osteoblast pyroptosis suppresses bone formation, osteoclast-associated pyroptotic signaling enhances bone resorption, and osteocyte pyroptosis disrupts mechanotransduction and microarchitectural integrity. Emerging data further reveal extensive crosstalk between pyroptosis, apoptosis, and necroptosis through PANoptotic signaling pathways, amplifying inflammatory bone damage. Experimental evidence from in vivo and in vitro models, together with emerging biomarker studies, consistently supports a central role for pyroptosis in diabetes-associated bone disease. Understanding the molecular regulation and temporal dynamics of pyroptosis in bone may provide novel therapeutic opportunities to preserve skeletal health in diabetic patients.
- 23 June 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 986
From sugar to flames: the detrimental role of pyroptosis in diabetes-associated bone loss
Diabetes mellitus (DM) is increasingly recognized as a major risk factor for skeletal fragility, characterized by impaired bone quality and increased fracture susceptibility. Chronic hyperglycemia induces metabolic stress, oxidative injury, and low-grade inflammation, all of which disrupt normal bone remodeling. Accumulating evidence indicates that pyroptosis, a highly inflammatory form of programmed cell death, has emerged as a critical mechanistic link between diabetes and bone loss. Pyroptosis is driven by inflammasome activation, particularly the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, leading to caspase-1 activation, gasdermin-mediated membrane pore formation, and the release of pro-inflammatory cytokines such as interleukin-1β (IL-1β) and interleukin-18 (IL-18). In the diabetic bone microenvironment, pyroptosis affects all major bone cell types. Osteoblast pyroptosis suppresses bone formation, osteoclast-associated pyroptotic signaling enhances bone resorption, and osteocyte pyroptosis disrupts mechanotransduction and microarchitectural integrity. Emerging data further reveal extensive crosstalk between pyroptosis, apoptosis, and necroptosis through PANoptotic signaling pathways, amplifying inflammatory bone damage. Experimental evidence from in vivo and in vitro models, together with emerging biomarker studies, consistently supports a central role for pyroptosis in diabetes-associated bone disease. Understanding the molecular regulation and temporal dynamics of pyroptosis in bone may provide novel therapeutic opportunities to preserve skeletal health in diabetic patients.